IRLAB THERAPEUTICS AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.4 SEK | +1.33% |
|
-0.87% | +52.00% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 2,551 | 1,578 | 2,173 | 2,277 | 1,987 | 591.3 | 591.3 | - |
| Enterprise Value (EV) 1 | 2,551 | 1,472 | 2,173 | 1,875 | 1,734 | 277.7 | 616.7 | 883.1 |
| P/E ratio | - | -15.4 x | -21.9 x | 44 x | -17.5 x | -2.19 x | -3.05 x | -3.07 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 13,018 x | 60,685 x | - | 11 x | 32.5 x | 68.5 x | 25 x | - |
| EV / Revenue | 13,018 x | 56,609 x | - | 9.02 x | 28.4 x | 48.9 x | 26.1 x | - |
| EV / EBITDA | - | -15.8 x | - | 33.5 x | -16 x | -1.57 x | -4.04 x | - |
| EV / FCF | - | -16.1 x | - | - | - | -1.68 x | - | - |
| FCF Yield | - | -6.21% | - | - | - | -59.5% | - | - |
| Price to Book | - | - | - | - | 6.83 x | - | - | - |
| Nbr of stocks (in thousands) | 40,500 | 43,110 | 51,748 | 51,748 | 51,868 | 51,868 | 51,868 | - |
| Reference price 2 | 63.00 | 36.60 | 42.00 | 44.00 | 38.30 | 11.25 | 11.25 | 11.25 |
| Announcement Date | 2/27/19 | 2/6/20 | 4/15/21 | 2/23/22 | 2/23/23 | 2/7/24 | - | - |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.196 | 0.026 | - | 207.8 | 61.14 | 5.678 | 23.65 | - |
| EBITDA 1 | - | -92.92 | - | 56.05 | -108.3 | -176.4 | -152.5 | - |
| EBIT 1 | - | -95.85 | - | 52.58 | -113.1 | -180.8 | -154.2 | - |
| Operating Margin | - | -368,646.15% | - | 25.3% | -185.01% | -3,183.6% | -652.15% | - |
| Earnings before Tax (EBT) 1 | - | -96.12 | - | 51.78 | -113.4 | -177.8 | -155.4 | -189.7 |
| Net income 1 | - | -96.12 | -91.65 | 51.78 | -113.4 | -177.8 | -155.4 | -189.7 |
| Net margin | - | -369,692.31% | - | 24.92% | -185.5% | -3,132.07% | -657.05% | - |
| EPS 2 | - | -2.370 | -1.920 | 1.000 | -2.190 | -3.430 | -3.690 | -3.660 |
| Free Cash Flow 1 | - | -91.34 | - | - | - | -165.2 | - | - |
| FCF margin | - | -351,300% | - | - | - | -2,908.65% | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 2/27/19 | 2/6/20 | 4/15/21 | 2/23/22 | 2/23/23 | 2/7/24 | - | - |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 Q1 | 2022 Q2 | 2022 Q3 |
|---|---|---|---|
| Net sales 1 | 9.042 | 23.41 | 16.5 |
| EBITDA 1 | -28.14 | -26.06 | -22.91 |
| EBIT 1 | -29.09 | -27.02 | -23.92 |
| Operating Margin | -321.7% | -115.4% | -144.97% |
| Earnings before Tax (EBT) 1 | -29.17 | -27.12 | -23.96 |
| Net income 1 | -29.17 | -27.12 | -23.96 |
| Net margin | -322.61% | -115.83% | -145.17% |
| EPS 2 | -0.5600 | -0.5200 | -0.4600 |
| Dividend per Share | - | - | - |
| Announcement Date | 5/11/22 | 8/24/22 | 11/9/22 |
1SEK in Million2SEK
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | 25.4 | 292 |
| Net Cash position 1 | - | 106 | - | 402 | 253 | 111 | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | -0.1662 x | - |
| Free Cash Flow 1 | - | -91.3 | - | - | - | -165 | - | - |
| ROE (net income / shareholders' equity) | - | -48.8% | - | - | -32.9% | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | 5.610 | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | - | - | - | 0.71 | 2.88 | 0.29 | 0.3 | - |
| Capex / Sales | - | - | - | 0.34% | 4.7% | 5.16% | 1.27% | - |
| Announcement Date | 2/27/19 | 2/6/20 | 4/15/21 | 2/23/22 | 2/23/23 | 2/7/24 | - | - |
1SEK in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +52.00% | 53.39M | |
| +33.50% | 664B | |
| +29.29% | 567B | |
| -7.50% | 354B | |
| +18.55% | 330B | |
| +4.61% | 286B | |
| +13.79% | 234B | |
| +4.93% | 199B | |
| -9.78% | 196B | |
| -4.83% | 148B |
- Stock Market
- Equities
- IRLAB A Stock
- Financials IRLAB Therapeutics AB
